Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival

K. V. Albuquerque; M. R. Price; R. A. Badley; I. Jonrup; D. Pearson; R. W. Blamey; J. F R Robertson

doi:10.1016/S0748-7983(95)96935-7

Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival

K. V. Albuquerque, M. R. Price, R. A. Badley, I. Jonrup, D. Pearson, R. W. Blamey, J. F R Robertson

Research output: Contribution to journal › Article › peer-review

54 Scopus citations

Abstract

The value of pre-treatment serum tumour marker levels in 85 consecutive patients of newly diagnosed metastatic breast cancer was prospectively assessed for predicting response to therapy and survival. The markers studied were carcinoembryonic antigen (CEA), orosomucoid (ORO), erythrocyte sedimentation rate (ESR), C reactive protein (CRP), ferritin (FERR), human milk fat globule membrane 1 and 2 (HMFGI and 2), CA 15-3 and NCRC-11. There was no correlation between serum marker levels and response to therapy. Only serum concentrations of CRP (P = 0.02), FERR (P = 0.001), HMFG1 (P = 0.004) and HMFG2 (P = 0.04) were predictive for survival. The prognostic significance of HMFG1 was restricted to a minority of patients (7%) with extreme values of these serum markers.

Original language	English (US)
Pages (from-to)	504-509
Number of pages	6
Journal	European Journal of Surgical Oncology
Volume	21
Issue number	5
DOIs	https://doi.org/10.1016/S0748-7983(95)96935-7
State	Published - Oct 1995

Keywords

metastatic breast cancer
overall survival
tumour markers

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/S0748-7983(95)96935-7

Cite this

Albuquerque, K. V., Price, M. R., Badley, R. A., Jonrup, I., Pearson, D., Blamey, R. W., & Robertson, J. F. R. (1995). Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. European Journal of Surgical Oncology, 21(5), 504-509. https://doi.org/10.1016/S0748-7983(95)96935-7

Albuquerque, KV, Price, MR, Badley, RA, Jonrup, I, Pearson, D, Blamey, RW & Robertson, JFR 1995, 'Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival', European Journal of Surgical Oncology, vol. 21, no. 5, pp. 504-509. https://doi.org/10.1016/S0748-7983(95)96935-7

@article{e158b875ff5d4c61a99766b100b5e5e0,

title = "Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival",

abstract = "The value of pre-treatment serum tumour marker levels in 85 consecutive patients of newly diagnosed metastatic breast cancer was prospectively assessed for predicting response to therapy and survival. The markers studied were carcinoembryonic antigen (CEA), orosomucoid (ORO), erythrocyte sedimentation rate (ESR), C reactive protein (CRP), ferritin (FERR), human milk fat globule membrane 1 and 2 (HMFGI and 2), CA 15-3 and NCRC-11. There was no correlation between serum marker levels and response to therapy. Only serum concentrations of CRP (P = 0.02), FERR (P = 0.001), HMFG1 (P = 0.004) and HMFG2 (P = 0.04) were predictive for survival. The prognostic significance of HMFG1 was restricted to a minority of patients (7%) with extreme values of these serum markers.",

keywords = "metastatic breast cancer, overall survival, tumour markers",

author = "Albuquerque, {K. V.} and Price, {M. R.} and Badley, {R. A.} and I. Jonrup and D. Pearson and Blamey, {R. W.} and Robertson, {J. F R}",

year = "1995",

month = oct,

doi = "10.1016/S0748-7983(95)96935-7",

language = "English (US)",

volume = "21",

pages = "504--509",

journal = "European Journal of Surgical Oncology",

issn = "0748-7983",

publisher = "W.B. Saunders Ltd",

number = "5",

}

TY - JOUR

T1 - Pre-treatment serum levels of tumour markers in metastatic breast cancer

T2 - a prospective assessment of their role in predicting response to therapy and survival

AU - Albuquerque, K. V.

AU - Price, M. R.

AU - Badley, R. A.

AU - Jonrup, I.

AU - Pearson, D.

AU - Blamey, R. W.

AU - Robertson, J. F R

PY - 1995/10

Y1 - 1995/10

N2 - The value of pre-treatment serum tumour marker levels in 85 consecutive patients of newly diagnosed metastatic breast cancer was prospectively assessed for predicting response to therapy and survival. The markers studied were carcinoembryonic antigen (CEA), orosomucoid (ORO), erythrocyte sedimentation rate (ESR), C reactive protein (CRP), ferritin (FERR), human milk fat globule membrane 1 and 2 (HMFGI and 2), CA 15-3 and NCRC-11. There was no correlation between serum marker levels and response to therapy. Only serum concentrations of CRP (P = 0.02), FERR (P = 0.001), HMFG1 (P = 0.004) and HMFG2 (P = 0.04) were predictive for survival. The prognostic significance of HMFG1 was restricted to a minority of patients (7%) with extreme values of these serum markers.

AB - The value of pre-treatment serum tumour marker levels in 85 consecutive patients of newly diagnosed metastatic breast cancer was prospectively assessed for predicting response to therapy and survival. The markers studied were carcinoembryonic antigen (CEA), orosomucoid (ORO), erythrocyte sedimentation rate (ESR), C reactive protein (CRP), ferritin (FERR), human milk fat globule membrane 1 and 2 (HMFGI and 2), CA 15-3 and NCRC-11. There was no correlation between serum marker levels and response to therapy. Only serum concentrations of CRP (P = 0.02), FERR (P = 0.001), HMFG1 (P = 0.004) and HMFG2 (P = 0.04) were predictive for survival. The prognostic significance of HMFG1 was restricted to a minority of patients (7%) with extreme values of these serum markers.

KW - metastatic breast cancer

KW - overall survival

KW - tumour markers

UR - http://www.scopus.com/inward/record.url?scp=0028802788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028802788&partnerID=8YFLogxK

U2 - 10.1016/S0748-7983(95)96935-7

DO - 10.1016/S0748-7983(95)96935-7

M3 - Article

C2 - 7589594

AN - SCOPUS:0028802788

SN - 0748-7983

VL - 21

SP - 504

EP - 509

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

IS - 5

ER -

Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this